The objective of this research is to understand the molecular genetic mechanisms responsible for regulating radiation-induced apoptotic cell death in tumor cells. This proposal is predicated on the hypothesis that apotosis is an important mode of cell death in some irradiated tumors and that tumor cell resistance to radiation may be due to the failure of the cell to undergo apoptosis. To examine this hypothesis we have developed a mouse lymphoma cell system that consists of two cell lines, one of which is sensitive to radiation-induced apoptosis and another that is resistant to radiation-induced apoptosis. The resistant line grew out of the sensitive line after long-term culture. We propose the following specific aims to illuminate these important mechanisms: 1. It is known that apoptosis is regulated in a number of normal processes by signal transduction and second messenger pathways. While less is known about radiation-induced apoptosis, we propose to investigate the role of these regulatory mechanisms in irradiated cells undergoing apoptosis using a new well-established battery of inhibitors of various steps in these pathways using our lymphoma system. This will initially focus on Ca++, calmodulin, protein kinase C and cAMP dependent protein kinase. 2. In a number of instances cell undergoing apoptosis are known to require nascent mRNA and protein synthesis. Several genes have been identified which appear to mediate or regulate apoptosis. We intend to examine the potential role of these genes in radiation-induced apoptosis. These genes include but are not limited to, SGP-2, transglutaminase, p53, fos, myc, jun, calmodulin and Bcl-2. Some of the effect of these genes is known to be mediated by cytokines (IL-2, IL-3, IL-6). Modulation of those genes involved in radiation-induced apoptosis by cytokines will also be examined. 3. We also propose to identify new genes associated with radiation-induced apoptosis by the method of substractive hybridization. Our apoptosis resistant and sensitive lymphoma model is well suited for this aspect. It is increasingly clear that apoptosis is highly regulated at the molecular level. By knowing what these mechanisms are and how they are influenced by exogenous agents such as growth factors and cytokines, we may ultimately be able to specifically enhance apoptosis in human tumors to overcome radioresistance in radiotherapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA062209-05
Application #
2654130
Study Section
Radiation Study Section (RAD)
Program Officer
Stone, Helen B
Project Start
1994-02-01
Project End
2000-01-31
Budget Start
1998-02-01
Budget End
2000-01-31
Support Year
5
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Radiation-Diagnostic/Oncology
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Somlo, George; Frankel, Paul H; Arun, Banu K et al. (2017) Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res 23:4066-4076
Kiesel, Brian F; Parise, Robert A; Tjørnelund, Jette et al. (2013) LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma. J Pharm Biomed Anal 81-82:89-98
Kirschbaum, Mark H; Goldman, Bryan H; Zain, Jasmine M et al. (2012) A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leuk Lymphoma 53:259-62
Kindler, Hedy L; Karrison, Theodore G; Gandara, David R et al. (2012) Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 30:2509-15
El-Khoueiry, A B; Ramanathan, R K; Yang, D Y et al. (2012) A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Invest New Drugs 30:1175-83
Mackay, H J; Buckanovich, R J; Hirte, H et al. (2012) A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. Gynecol Oncol 125:136-40
Kirschbaum, Mark; Frankel, Paul; Popplewell, Leslie et al. (2011) Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 29:1198-203
Ramalingam, Suresh S; Davies, Angela M; Longmate, Jeffrey et al. (2011) Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). J Thorac Oncol 6:1741-5
Lara Jr, Primo N; Longmate, Jeff; Reckamp, Karen et al. (2011) Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer 12:33-7
Somlo, George; Lashkari, Ashkan; Bellamy, William et al. (2011) Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial. Br J Haematol 154:533-5

Showing the most recent 10 out of 25 publications